News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH reaffirms Buy recommendation for Formycon AG and lowers price target to €80 amid expected launch of lucrative biosimilar FYB202. Analyst Simon Scholes provides insights on Formycon's future prospects and market dynamics -
-
-
COMMUNIQUÉ DE PRESSE
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Formycon initiates clinical program for FYB206, a biosimilar candidate for Keytruda, targeting immuno-oncology. Phase I and III trials underway to assess safety, efficacy, and PK equivalence -